Abstract
<h3>Aim</h3> To evaluate the Quality of Life (QoL) after organ-sparing therapy for T2–T3 bladder cancer. <h3>Patients and methods</h3> We pointed out that the main QoL domains after bladder-sparing therapy are similar to these of patients (pts) affected by prostatic cancer. So we developed an autocompilative questionnaire proceeded in many domains from EORTC questionnaire for prostatic cancer QoL. We performed a cross-cultural adaptation process and validated the translation from the original language. The answers were weighted by a different numeric value and several summary scores reflecting the main QoL domains were obtained. The highest values showed a better QoL degree. We mailed this questionnaire to 50 pts treated in our institutions by radiotherapy (34 pts) or concomitant radiochemotherapy (16 pts). Until now 30 questionnaires returned; of these 24 are evaluable. All pts were free of local recurrence and not underwent salvage cystectomy. <h3>Results</h3> Most of the pts showed a good QoL, generally obtaining a high score in all domains. In a scale ranging from 1 to 4, 50% of the pta had a physical score≥3,83.3% a symptomatic score≥3, 57.1% a sexual score≥3,87.5% a general score≥3; in a scale ranging from 1 to 2, 70.8% pts had a psychological score≥1.5 and 100% a relational score≥1.5. <h3>Conclusion</h3> The organ-sparing therapy for bladder cancer allows a good QaL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
